Top

Published in:

01-07-2009 | ORIGINAL ARTICLE – CONSENSUS REPORT: RESECTABLE AND BORDERLINE RESECTABLE PANCREAS CANCER

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

Authors: Mark P. Callery, MD, Kenneth J. Chang, MD, Elliot K. Fishman, MD, Mark S. Talamonti, MD, L. William Traverso, MD, David C. Linehan, MD

Published in: Annals of Surgical Oncology | Issue 7/2009

Excerpt

Currently, multidetector computed tomography (CT) with three-dimensional (3-D) reconstruction is the preferred method to diagnose and stage pancreatic cancer. Magnetic resonance imaging and magnetic resonance imaging cholangiopancreatography can also detect primary tumors (hypointense on T1-weighted image) as well as regional and distant metastasis, but no clear advantage over CT has been demonstrated.1 Magnetic resonance imaging cholangiopancreatography allows for visualization of the bile duct and pancreatic duct similar to endoscopic retrograde cholangiopancreatography (ERCP) but adds little to the assessment of resectability. The routine use of ERCP for diagnosis is not supported, but therapeutic ERCP may be considered in symptomatic patients with obstructive jaundice (e.g., moderate to severe pruritus) who are awaiting surgery. Endoscopic ultrasound (EUS) may be more sensitive than CT in detecting small tumors and can be useful in patients with obstructive jaundice and no mass or an atypical/questionable mass seen on CT. Its usefulness (especially in obtaining a pretreatment tissue diagnosis when warranted) is addressed later in the manuscript. …

Reinhold C. Magnetic resonance imaging of the pancreas in 2001. J Gastrointest Surg. 2002;6:133–5PubMedCrossRef

Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine–18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144–51PubMedCrossRef

Heinrich S, Goerres GG, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235–43PubMedCrossRef

Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923–9PubMedCrossRef

Goh BKP. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2006;243:709–10.PubMedCrossRef

McNulty NJ, Francis IR, Platt JF, et al. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220:97–102PubMed

Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am. 2002;40:1263–72PubMedCrossRef

Megibow AJ, Babb JS, Hecht EM, et al. Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology. 2006;238:87–95PubMedCrossRef

Raptopoulos V, Steer ML, Sheiman RG, et al. The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR Am J Roentgenol. 1997;168:971–7PubMed

10.

House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004;8:280–8PubMedCrossRef

11.

Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol. 2004;182:619–23PubMed

12.

Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439–43PubMed

13.

Chang KJ. EUS-guided fine needle injection (FNI) and anti-tumor therapy. Endoscopy. 2006;38 Suppl 1:S88–93PubMedCrossRef

14.

Chang KJ. State-of-the-art lecture: endoscopic ultrasound (EUS) and FNA in pancreatico-biliary tumors. Endoscopy. 2006;38(Suppl 1):S56–60PubMedCrossRef

15.

Boujaoude J. Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol. 2007;13:3662–6PubMed

16.

Jhala NC, Jhala D, Eltoum I, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions. Cancer. 2004;102:239–46PubMedCrossRef

17.

Eloubeidi MA, Tamhane A, Varadarajulu S, Wilcox CM. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc. 2006;63:622–9PubMedCrossRef

18.

Paquin SC, Gariepy G, Lepanto L, et al. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc. 2005;61:610–1PubMedCrossRef

19.

Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003;58:690–5PubMedCrossRef

20.

Erickson RA, Garza AA. Impact of endoscopic ultrasound on the management and outcome of pancreatic carcinoma. Am J Gastroenterol. 2000;95:2248–54PubMedCrossRef

21.

Chen VK, Arguedas MR, Kilgore ML, Eloubeidi MA. A cost-minimization analysis of alternative strategies in diagnosing pancreatic cancer. Am J Gastroenterol. 2004;99:2223–34PubMedCrossRef

22.

National Comprehensive Cancer Network (NCCN). NCCN updates pancreatic adenocarcinoma guidelines. November 26, 2007. Available at: http://www.nccn.org/about/news/newsinfo.asp?NewsID=124. Accessed February 23, 2009

23.

Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46PubMedCrossRef

24.

Potter MW, Shah SA, McEnaney P, Chari RS, Callery MP. A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol. 2000;9:103–10PubMedCrossRef

25.

Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 2006;17:189–99PubMedCrossRef

26.

Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223:134–40PubMedCrossRef

27.

Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135:409–14PubMedCrossRef

28.

Thomson BN, Parks RW, Madhavan KK, Wigmore SJ, Garden OJ. Early specialist repair of biliary injury. Br J Surg. 2006;93:216–20PubMedCrossRef

29.

Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg. 1997;1:236–43PubMedCrossRef

30.

Zamboni GA, Kruskal JB, Vollmer CM, et al. Pancreatic adenocarcinoma: value of multidetector CT angiography in preoperative evaluation. Radiology. 2007;245:770–8PubMedCrossRef

31.

Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88:325–37PubMedCrossRef

32.

Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg. 2002;235:1–7PubMedCrossRef

33.

Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9:1286–92PubMedCrossRef

34.

Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc. 2005;19:638–42PubMedCrossRef

35.

Ferrone CR, Haas B, Tang L, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10:1347–53PubMedCrossRef

Title: Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Authors: Mark P. Callery, MD
Kenneth J. Chang, MD
Elliot K. Fishman, MD
Mark S. Talamonti, MD
L. William Traverso, MD
David C. Linehan, MD
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0408-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2009

AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the Conference

Prognostic Significance of Tumor Size in T3 Gastric Cancer

Prophylactic Total Gastrectomy (PTG) for Hereditary Diffuse Gastric Cancer (HDGC): The Newfoundland Experience with 23 Patients

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Callery et al.

Adjustment of N Stages of Gastric Cancer by the Ratio Between the Metastatic and Examined Lymph Nodes

Centralization of Esophageal Cancer Surgery: Does It Improve Clinical Outcome?